Beck Anxiety Inventory (BAI)
Research Papers
Neurofeedback Rehabilitation Reduces Anxiety in Methamphetamine Abusers
Addictive disorders are characterized by cognitive, behavioral, and neurological impairments caused by dysregulations of brain structure that can extend well beyond early withdrawal in the months and years of recovery. The present study aimed to examine the efficacy of neurofeedback rehabilitation on anxiety in methamphetamine abusers. The sample consisted of 14 male methamphetamine drug addicts who were randomly assigned to an experimental group (n = 7) and a control group (n = 7). Participants were assessed for Axis I disorders (SCID) and the Beck Anxiety Inventory (BAI). Mixed repeated ANOVA, independent t-tests, and chi-square were used for data analysis. The experimental group received 18 sessions of neurofeedback rehabilitation and standard psychological interventions treatment as usual, while the control group received only standard interventions. Results showed that neurofeedback significantly reduced anxiety in methamphetamine abusers at posttreatment and during a one-month follow-up. Along with other psychological interventions, neurofeedback rehabilitation is recommended for methamphetamine abusers
View Full Paper →Healing the Neurophysiological Roots of Trauma: A Controlled Study Examining LORETA Z-Score Neurofeedback and HRV Biofeedback for Chronic PTSD
Introduction: Posttraumatic stress disorder (PTSD) has been linked to abnormalities within three neural networks: default mode (DMN), salience (SN), and central executive (CEN). This study examined the effectiveness of LORETA z-score neurofeedback (LZNF) training for altering current source within these networks and reducing symptoms associated with PTSD. Methods: Twenty-three adults with chronic PTSD were randomly assigned to 15 sessions of either LZNF (n = 12) or heart rate variability biofeedback (HRVB; n = 11). Psychosocial and physiological assessments were completed at baseline and postintervention. Results: The LZNF group showed very large, statistically significant decreases in symptoms on the PTSD Checklist for DSM-V (PCL-5; p = .003, d = 2.09) and Beck Anxiety Inventory (BAI; p = .003, d = 2.13). The HRVB group also showed very large decreases on the PCL-5 (p = .006, d = 1.40) and medium effects on the BAI (p = .018, d = 0.76). Between-group comparisons showed medium to large effects of group type in favor of LZNF (PCL-5 d = 0.57; BAI d = 0.94), although not statistically significant. LZNF Responders (n = 9) demonstrated very large, statistically significant decreases in abnormal z-scores within all targeted networks (DMN p = .012, d = 0.96; SN p = .008, d = 1.32; CEN p = .008, d = 1.33). Conclusion: The positive outcomes of this study provide preliminary evidence to support LZNF training as a specific, effective, and tolerable intervention for adults with chronic PTSD
View Full Paper →The Efficacy of Neurofeedback in Patients with Major Depressive Disorder: An Open Labeled Prospective Study
Abstract The purpose of this study was to evaluate the effect of neurofeedback on depressive symptoms and electrophysiological disturbances in patients with major depressive disorder. We recruited participants suffering from depression to evaluate efficacy of left prefrontal beta with alpha/theta training. An 8-week, prospective, openlabel study was undertaken. Twenty participants were recruited. The treatment protocol was twice or three times a week training of beta at F3 with alpha/theta at Pz for 8 weeks. When every visit, patients were received beta training for 30 min, and then alpha/theta training for 30 min. Baseline, 4 and 8 week scores of; the Hamilton rating scale for Depression (HAM-D), the Hamilton rating scale for Anxiety (HAM-A), the Beck Depression Inventory (BDI)-II, the Beck Anxiety Inventory (BAI), Clinical global impression-severity (CGI-S), and pre- and posttreatment resting state EEGs were compared. Interhemispheric alpha power asymmetry (A score) was computed for homologous sites F3–F4. Pre- and post-training clinical assessments revealed significant improvements in HAM– D, HAM-A, BDI, and CGI-S scores. Cumulative response rates by HAM-D were 35.0 and 75.0 % at 4 and 8 weeks, respectively, corresponding cumulative remission rates by HAM-D were 15.0 and 55.0 %, respectively. No significant differences were found between pre- and post-treatment A score. Neurofeedback treatment could improve depressive symptoms significantly. In addition, anxiety symptoms and clinical illness severity decreased significantly after neurofeedback treatment. Despite its several limitations, such as, small sample size and lack of a control group, this study suggested neurofeedback has significant effects in patients with major depressive disorder. Neurofeedback Beta training Depression Asymmetry score
View Full Paper →Ready to Optimize Your Brain?
Schedule a free consultation to discuss beck anxiety inventory (bai) and how neurofeedback training can help
Or call us directly at 855-88-BRAIN
View Programs & Pricing →